Recaticimab lowered cholesterol with or without coronary disease
A pooled analysis of four randomized trials in 1,120 people with high blood fats found reductions versus placebo after 12 or 16 weeks.
16 weeks
Limit: Different statin use complicates comparing recaticimab’s effects between patients with and without coronary disease
Edited by Boris Djordjevic · AgingResearch.News
The pooled analysis of four randomized trials included 1,120 people with high cholesterol or mixed blood-fat abnormalities. Of these, 353 had coronary artery disease, which affects blood flow to the heart, and 767 did not. Those with coronary disease were older (57 versus 47 years) and more often male (72% versus 52%).
Researchers compared recaticimab at 150 mg every four weeks or 300 mg every eight weeks with placebo, assessing blood fats at weeks 12 and 16, respectively. Recaticimab lowered “bad” cholesterol and other blood fats versus placebo in both groups. Those with coronary disease also took statins, cholesterol-lowering medicines; approximately two-thirds without it received recaticimab alone. Treatment-related adverse events occurred in 27.7% on recaticimab versus 24.3% on placebo among those with coronary disease, and 21.4% versus 16.2% among those without it. Most were mild.
Why it matters
Coronary artery disease is a concern in later life, and affected patients face a high risk of recurrent cardiovascular events. The analysis informs efforts to help these patients reach recommended blood-fat targets.
Caveats
Blood-fat changes do not establish whether the drug prevented heart attacks or strokes. This conference abstract concerns people with high cholesterol or mixed blood-fat abnormalities and does not report longer-term cardiovascular outcomes.
The paper
Nanjing Medical University
ESC Congress 2026 Abstract, Oct 26, 2026, Open access
Presented at ESC Congress 2026
